Revance Therapeutics Inc (NASDAQ: RVNC) kicked off on Tuesday, up 5.79% from the previous trading day, before settling in for the closing price of $3.80. Over the past 52 weeks, RVNC has traded in a range of $2.30-$9.74.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 815.27%. While this was happening, its average annual earnings per share was recorded 40.79%. With a float of $95.70 million, this company’s outstanding shares have now reached $104.90 million.
The extent of productivity of a business whose workforce counts for 597 workers is very important to gauge. In terms of profitability, gross margin is 70.66%, operating margin of -67.21%, and the pretax margin is -72.59%.
Revance Therapeutics Inc (RVNC) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Revance Therapeutics Inc is 8.77%, while institutional ownership is 79.62%. The most recent insider transaction that took place on Nov 18 ’24, was worth 16,296. In this transaction CMO & Global Therapeutics Lead of this company sold 3,908 shares at a rate of $4.17, taking the stock ownership to the 104,945 shares. Before that another transaction happened on Apr 16 ’24, when Company’s Chief Commercial Officer sold 2,392 for $3.80, making the entire transaction worth $9,096. This insider now owns 114,864 shares in total.
Revance Therapeutics Inc (RVNC) Performance Highlights and Predictions
In the latest quarterly report, which was put into the public domain on 9/30/2024, the organization reported -0.61 earnings per share (EPS), higher than consensus estimate (set at -0.92) by 0.31. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.3 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 40.79% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 11.60% during the next five years compared to 0.57% growth over the previous five years of trading.
Revance Therapeutics Inc (NASDAQ: RVNC) Trading Performance Indicators
Take a look at Revance Therapeutics Inc’s (RVNC) current performance indicators. Last quarter, stock had a quick ratio of 3.05. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.71.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.92, a number that is poised to hit -0.21 in the next quarter and is forecasted to reach -0.76 in one year’s time.
Technical Analysis of Revance Therapeutics Inc (RVNC)
The latest stats from [Revance Therapeutics Inc, RVNC] show that its last 5-days average volume of 1.54 million was inferior to 2.73 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 35.76%. Additionally, its Average True Range was 0.33.
During the past 100 days, Revance Therapeutics Inc’s (RVNC) raw stochastic average was set at 32.56%, which indicates a significant increase from 25.98% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 206.60% in the past 14 days, which was higher than the 147.99% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $5.05, while its 200-day Moving Average is $4.58. Now, the first resistance to watch is $4.19. This is followed by the second major resistance level at $4.36. The third major resistance level sits at $4.52. If the price goes on to break the first support level at $3.86, it is likely to go to the next support level at $3.70. Assuming the price breaks the second support level, the third support level stands at $3.53.
Revance Therapeutics Inc (NASDAQ: RVNC) Key Stats
The company with the Market Capitalisation of 421.71 million has total of 104,902K Shares Outstanding. Its annual sales at the moment are 234,040 K in contrast with the sum of -323,990 K annual income. Company’s last quarter sales were recorded 59,880 K and last quarter income was -38,120 K.
